Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupradiotherapyThoracic TumorsDiseaseLung Carcinoma, Non-Small CellSubgroupnon-squamousICD10C34.-MeSHSequenceCALGB 9431: VINO25/CISP80, NSCLC, A (PID261) -|- VINO15/CISP80/Radiation, B (PID262).CISP60/ETOP150, NSCLC, neoadj., C1-3 (PID620) -|- CISP50/ETOP100/Radiation, C1 (PID619).ESPATUE: PACL175/CISP50, NSCLC, ind., neoadj., A (PID 852) -|- VINO20/CISP50/Radiation B (PID 853) -|- possibly VINO15/CISP40/Radiation C (PID1169)PACL45/CRBP2/Radiation, NSCLC A (PID253) -|- PACL200/CRBP6 cons., B (PID254)PACL50/CRBP2/Radiation, NSCLC A (PID255) -|- PACL200/CRBP6 cons., B (PID256)PEME500/CISP75/Radiation, NSCLC, A (PID247) -|- PEME500 cons., B (PID249).PEME500/CRBP5/Radiation, NSCLC (Adeno) A (PID250) -|- PEME500 cons., B (PID251)ChemotherapyChemo-substanceCarboplatinCisplatinDurvalumabEtoposidePaclitaxelPemetrexedVinblastineVinorelbineChemo-substanceCarboplatinCisplatinDurvalumabEtoposidePaclitaxelPemetrexedVinblastineVinorelbineChemo-substanceCarboplatinCisplatinDurvalumabEtoposidePaclitaxelPemetrexedVinblastineVinorelbineChemo-substanceCarboplatinCisplatinDurvalumabEtoposidePaclitaxelPemetrexedVinblastineVinorelbineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances14679Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseConsolidationInductionneoadjuvantTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAnorexiaAstheniaCardiotoxicityDehydrationDiarrheaDyspneaEmetogenicity (MASCC/ESMO)EsophagitisFatigueFebrile NeutropeniaGastrointestinal ToxicityHyperglycemiaHypokalemiaHypotensionHypothyroidismInfectionsInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeutropeniaOral MucositisPneumoniaPneumonitisPruritusRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorAlbain KSAntonia SBelani CPChoy HCurran WEberhardt WHirose TKawaguchi TSemrau SVokes EEDiseaseFortgeschrittenes, nichtkleinzelliges Lungenkarzinom, Stadium IIIA und IIIB, Erstlinie, ECOG 0-1fortgeschrittenes NSCLC, nichtresezierbares, Stadium III, ECOG 0-1lokal fortgeschrittenes, nichtresektables, nichtkleinzelliges Lungenkarzinom, Stadium III, nach Platin und Radiotherapie, ECOG 0-1nicht resezierbares NSCLC, Stadium I-IIIB, ECOG 0-3Nicht resezierbares NSCLC, Stadium IIIA und IIIB, Erstlinie, ECOG 0-2NSCLC (Adeno-) Stadium IIIA und IIIB (ohne Pleuraerguss), ECOG 0-1NSCLC, potenziell resezierbar, Stadium IIIA oder IIIB, ECOG 0-1NSCLC, Stadium IIIa und IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIa und Stadium IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium II und III, nicht resezierbar, Karnofsky > 70NSCLC Stadium IIIa und Stadium IIIbNSCLC Stadium IIIbNSCLC Stadium III nicht resezierbarOriginBelani CP, University of Pittsburgh Cancer Institute, USACancer and Leukemia Group B Studie 9431Cancer Center and Research Institute, Magnolia, Tampa, PACIFIC StudieChoy H, University of Texas Southwestern, Dallas, TexasChoy H, Vanderbilt University Medical School, Nashville, USADepartment of Internal Medicine and Radiotherapy, West German Cancer Center University, EssenDepartment of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, ESPATUEDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, RTOG 9410Department of Radiotherapy, University of Rostock, Germany, PET-PlanNational Hospital Organization, Kinki-Chuo Chest Medical Center, JapanSouthwest Oncology Group, SWOG 9019The First Department of Internal Medicine, Showa University School of Medicine, Tokyo, JapanProtocols in Revision 23 protocols foundProtocols under revision.Cisplatin 100 / Vinblastine 5 / Radiation, Non-Small Cell Lung Cancer (PID857 V1.1)Cisplatin 20 / Vinorelbine 12.5 / Radiation, Non-Small Cell Lung Cancer (PID669 V1.1)Cisplatin 50 / Etoposide 100 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 4 (PID619 V1.1)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer (PID252 V2.1)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer, Variant 1 (PID858 V1.2)Cisplatin 60 / Etoposide 150, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-3 (PID620 V1.1)Durvalumab 10, Non-Small Cell Lung Carcinoma (PID470 V1.0)Paclitaxel 175 / Cisplatin 50, Non-Small Cell Lung Cancer, Induction, Neoadjuvant, Part A (PID852 V1.2)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID254 V1.1)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID256 V1.1)Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID253 V1.1)Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID255 V1.2)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer, (Adeno) Part A (PID250 V1.0)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer (Adeno) Part B (PID251 V1.0)Pemetrexed 500 / Cisplatin 75 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID249 V1.0)Pemetrexed 500 / Cisplatin 75 / Radiation, Non-Small Cell Lung Cancer, Part A (PID247 V1.1)Vinorelbine 12.5 / Carboplatin 1 / Radiation, Non-Small Cell Lung Cancer (PID668 V1.0)Vinorelbine 15 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer, Part C (PID1169 V1.1)Vinorelbine 15 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer, B (PID262 V1.1)Vinorelbine 20 / Cisplatin 50 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Part B (PID853 V1.1)Vinorelbine 20 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer (PID1193 V1.1)Vinorelbine 20 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer (PID646 V1.1)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Cancer, A (PID261 V1.2)
